Better Health for All

Precigen, formerly Intrexon Corporation, demonstrates a strong commitment to improving health outcomes through its core business and significant R&D investment. Its primary product, PAPZIMEOS™ (PRGN-2012), received full FDA approval in August 2025 as the first and only therapy for adults with recurrent respiratory papillomatosis (RRP), a rare, debilitating, and potentially life-threatening disease.

This therapy addresses the root cause of RRP, with a pivotal study showing 51% of patients achieved a complete response (no surgeries in 12 months), and 86-95% experienced a reduction in surgeries. The therapy was well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2. The company's research and development expenses were $53,070 thousand in 2024, significantly exceeding its total revenues of $3,925 thousand, indicating a substantial allocation to health innovation. The company also maintains excellent risk transparency, providing "Important Safety Information" detailing potential side effects for PAPZIMEOS and encouraging reporting of adverse events to both the FDA and the company.

Fair Pay & Worker Respect

None of Precigen's employees are represented by a collective bargaining agreement.

As of December 31, 2024, the company had 143 employees. On August 6, 2024, Precigen announced a workforce reduction of over 20%. In connection with the workforce reduction, Precigen recorded a charge related to employee severance and termination benefits of $2.1 million, which were paid in the third quarter of 2024. Compensation packages include a competitive base salary and bonus, the issuance of equity incentives, a 401(k) plan, and health and wellness benefits, including a health insurance plan with a Platinum actuarial value. In 2024, employee development initiatives included employee training targeting specific areas of interest, executive and manager coaching, and performance management, which encompass performance goals and competency evaluations.

Honest & Fair Business

No specific, concrete data points were found in the provided articles for any of the 'Honest & Fair Business' KPIs. The articles primarily focus on financial results, clinical trial progress, and general business updates for Precigen, Inc. (formerly Intrexon Corporation). Information regarding regulatory fines

, transparency index scores , whistleblower policies , financial restatements , audit coverage , ESG controversies , complaint resolution times , board conflict-free percentages , anti-corruption policies , or third-party verification of ethical claims was either explicitly marked as 'N/A' , 'Not mentioned' , or 'null' in the evidence, or was entirely absent. Therefore, all KPIs are omitted due to lack of evidence.

Respect for Cultures & Communities

Oxitec, a subsidiary of Intrexon Corporation, has established over 20 formal partnerships, including more than 10 with governments and international organizations and more than 10 with civil society organizations.

The company demonstrates a high level of social license for its operations, with over 94% public acceptance for the OX5034 Mini-Capsule Pilot in Indaiatuba, Brazil. In Piracicaba, Brazil, support for Friendly™ Aedes was 92.8% in November 2016. Furthermore, a 2016 public referendum on Oxitec’s mosquito technology received support in 31 out of 33 Monroe County precincts.